Table 2.
Primary and secondary outcomes
| Outcomes | No. of events, n (%) |
Unadjusted HR | Adjusted HR* | ||||
|---|---|---|---|---|---|---|---|
| GLP-1RA (n = 105) | No GLP-1RA (n = 1316) |
P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| All-cause mortality | 38 (36) | 680 (52) | 0.002 | 0.61 (0.44; 0.85) | 0.003 | 0.60 (0.43; 0.84) | 0.003 |
| Ischemic stroke | 12 (11) | 134 (10) | 0.69 | 0.99 (0.55; 1.79) | 0.97 | 1.05 (0.57; 1.94) | 0.88 |
| Recurrent MI | 24 (23) | 258 (20) | 0.42 | 1.05 (0.69; 1.59) | 0.83 | 0.74 (0.48; 1.15) | 0.18 |
| Heart Failure | 29 (28) | 433 (33) | 0.27 | 0.74 (0.51; 1.08) | 0.15 | 0.71 (0.48; 1.05) | 0.09 |
*Adjusted for age, sex, hyperlipidaemia, hypertension, complication to diabetes, metformin, insulin, statins, angiotensin converting enzyme/angiotensin-II inhibitor, loop diuretics, acetylsalicylic acid, combinational diuretics, and time from diabetes to ST-segment elevation myocardial infarction
CI: Confidence interval; GLP-1RA: Glucagon-like peptide-1 receptor agonist; HR: hazard ratio